Earlier alignment on trial design, evidence generation and geography can help emerging biopharma companies navigate ...

Agile CDMO partnerships can preserve scientific knowledge, reduce handoff risk and help programs move more smoothly from ...

Technology transfer creates plenty of documentation. Process descriptions, risk assessments, batch records, specifications, ...

Diversifying API sourcing and building qualified alternatives can help manufacturers reduce exposure to geographic ...

Understanding a CDMOs operating model under uncertainty can help determine whether it is the right partner for the program.

How early risk identification, standardized processes and digital technologies can help sponsors streamline technology ...

For high-dose, high-concentration biologics, early alignment preserves flexibility, exposes risks before they become expensive and avoids constraints in manufacturing, clinical de ...

Stage-appropriate development can help lean biotech teams preserve capital, manage risk and maintain momentum without closing ...

Mike Stenberg, VP, Business Development, LGM Pharma, discusses LGM's strategic expansion, lessons learned from previous ...

Biopharma companies are looking beyond available capacity to CDMO networks that can adapt across sites, scales and changing ...

Building flexibility into study design and using just-in-time supply models can help sponsors adapt to disruption, reduce ...

Thermo Fisher's Chad Schwartz, Director Product Management, Cell Culture, & Anish Parikh, VP Commercial Ops, Pharma Services, ...